#Sars

Deepta Bhattacharya

deeptabhattacha

I received this email from someone last week that I can't stop thinking about. I probably received this since I have been openly optimistic about vaccine efforts. So I wanted

Andrew💙Croxford

andrew_croxford

NEW THREAD: possible development of anti-Syncytin responses after immunization with the SARS-CoV-2 spike protein-coding mRNA vaccines, based on a "homologous" region shared between these proteins. Syncytin-1 is involved in human

Michael Mina

michaelmina_lab

NEW RESULTS:Rapid Antigen tests work v well!Not all are same - Some much better than othersThis paper is a masterclass of how to study AND interpret the use of #COVID19

C. Michael Gibson MD

CMichaelGibson

Many have become numb to pandemic statisticsHealthcare workers, though, must face the reality that there are now MORE PATIENTS HOSPITALIZED THAN AT ANY TIME in 2020, 40% more than 2

Katarina Braun

KATarinambraun

Preprint Using viral sequencing + some epi data, we show that a majority #SARSCoV2 infections in healthcare workers at our institution occur in the community and can only rarely be

Claudina MICHAL-TEITELBAUM

MartinFierro769

1/n Court thread sur la récente propagation d'une variante du SARS-CoV-2 en UK. Origine? Diffusion? Risques? 2/n Une variante d'un virus apparaît lorsque un nombre suffisant de mutations s'accumulent faisant

Juan Cambeiro💡

juan_cambeiro

Reposting to make some minor corrections. Building on @kristjanmoore and using info available up to today, I assign a 90% probability to at least one of the new variants being

Yardley Yeadon

MichaelYeadon3

https://apps.who.int/iris/bitstream/handle/10665/329438/9789241516839-eng.pdf#page=9Does anyone have an explanation for why we’re doing almost all of the things which, last year, were explicitly NOT recommended under any circs in relation

💚JS100 I'm not working for the clampdown🙂

js100js100

THREAD OF COVID QUESTIONS AND ANSWERS - My opinions and answers. Don't treat them as fact, make your own minds up. DOES SARS-COV-2 VIRUS EXIST? - Don't know/not certain/not

John Lam - It's OK!

john_lam

THREAD 1. Today's announcement of the 90% efficacy of the Pfizer vaccine, BNT162b2, from preliminary analysis of their Phase 3 study was more great news today. So I'm writing this

Dr Lindsay Broadbent

LindsayBbent

Plaque assays are how we work out how much SARS-COV-2 we have in a sample. And they’re great to illustrate how infections in people work too! The virus causes damage

Jeremy Farrar

JeremyFarrar

World needs to know. A text this evening from colleague in middle income country. "We have a disaster here. Hospitals overwhelmed, critical oxygen shortages, soaring COVID numbers. New variant SARS-

Allen Cheng

peripatetical

SARS-CoV-2 infection in patients that don't have symptoms. It's complicated. A thread. Data suggest that viral load does start to increase and is maximal slightly before the onset of symptoms,

Hilda Bastian, PhD

hildabast

Preprint of the South African phase 1b/2 trial for the Oxford/AstraZeneca vaccine is online. Primary efficacy analysis is for 2,026 people who weren't infected with HIV (there was also a

TrekkerTeach

trekkerteach12

My fear is that this is what's happening in the US, especially California.Cases going down, but #B117 and other new variants here and spreading...all while restrictions are being lifted and

Natalie E. Dean, PhD

nataliexdean

As @hankgreen nicely points out, we have to be careful that "we don't know whether the vaccine reduces transmission" doesn't morph into "the vaccine doesn't reduce transmission." How do we

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.